GlassScriptPhysician profile
Robert T Richards
NPI 1992137517
$4,864.68
in general payments reported to CMS, 2019-2025
26 companies · $659 in 2025
The $659 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $974 · 2023: $1,469 · 2024: $722 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,385.47 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $421.62 | 2021-2023 | Breztri, Brilinta |
| Lilly USA, LLC | $344.19 | 2022-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $327.42 | 2022-2023 | |
| Scpharmaceuticals INC. | $299.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.27 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $219.94 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $212.02 | 2023-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $204.86 | 2021-2023 | |
| Esperion Therapeutics, INC. | $184.86 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $158.64 | 2023-2024 | Ingrezza |
| Genentech USA, INC. | $124.99 | 2025 | Xolair |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | Koselugo |
| Lexicon Pharmaceuticals, INC. | $102.40 | 2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $85.69 | 2022-2025 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $81.79 | 2022 | |
| Amgen INC. | $67.17 | 2022-2023 | Repatha |
| Gebauer Company | $57.57 | 2025 | |
| Novo Nordisk INC | $55.54 | 2022-2023 | Ozempic |
| Abbott Laboratories | $51.71 | 2021-2025 | Gallant |
| Tactile Systems Technology INC | $46.59 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Amarin Pharma, INC. | $19.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.34 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $17.83 | 2022 | |
| Pfizer INC. | $14.84 | 2023 | |
| Boston Scientific Corporation | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.